PatentsUSA
Samchundang Pharm Secures Pivotal Settlement in Eylea Biosimilar Patent Dispute, Paving Way for Global Market Entry
Samchundang Pharm has concluded a significant settlement in its patent dispute concerning a biosimilar version of Eylea, the blockbuster ophthalmic drug. This resolution removes key legal barriers, positioning the company to advance global commercialization efforts. The settlement marks a critical development in biosi…
Tuesday, August 18, 2026